Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT03082534 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT03082534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03082534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
University of California, San Diego
Phase
Phase 2
Overall status
Completed
Start date
March 28, 2017
Completion date
September 11, 2025
Enrollment
78 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma, head and neck cancer, head and neck neoplasms, head and neck squamous cell carcinoma, hnscc, hypopharynx cancer, larynx cancer, lip scc, nasopharynx cancer, oral cavity cancer, oropharynx cancer, sinonasal carcinoma